C.R.Bard
This article was originally published in The Gray Sheet
Executive Summary
Firm plans to launch palladium and iodine brachytherapy seeds for treatment of benign prostatic hyperplasia by the end of the second quarter, company Chairman and CEO William Longfield reports at a Feb. 2 session of the U.S. Bancorp Piper Jaffray Health Care Conference in New York City. The firm will "accelerate [its] position to market very quickly," Longfield notes. Separately, Bard expects to commence by mid-February a Phase II clinical trial of an endoluminal graft for minimally invasive treatment of abdominal aortic aneurysms. The company had announced an exclusive agreement with California-based Endologix on Aug. 16 for distribution rights in Europe and Australia (1"The Gray Sheet" Sept. 20, p. 13). Longfield reiterates a previous pledge to buy Endologix this year